These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23947968)

  • 1. Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey.
    Türel O; Kisa A; McIntosh ED; Bakir M
    Value Health; 2013; 16(5):755-9. PubMed ID: 23947968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
    Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
    Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Giglio N; Gentile A; Jimenez SG; Jáuregui B; Clark AD; Diosque M; Vizzotti C
    Vaccine; 2011 Jul; 29(31):4963-72. PubMed ID: 21621575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
    Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
    Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
    Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.
    Bakır M; Türel O; Topachevskyi O
    BMC Health Serv Res; 2012 Nov; 12():386. PubMed ID: 23137037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.